Evidence digest
Ipamorelin has a small early-phase human literature that was not carried forward to approval. Development programmes are abandoned for many reasons — commercial, strategic and scientific — and the published record does not establish a durable clinical effect. A discontinued programme is not evidence of efficacy, and it is not evidence of harm either; it is an absence of conclusion.
Updated 22 Jul 2026 · 3 studies indexed · 3 human · compound record
Next Gen Peptides$4.20/mg listed · 2 Ipamorelin certificates93.1of 100Extensively documentedVisit Next Gen Peptides
PeptidePlugs$4.00/mg listed · 3 Ipamorelin certificates91.3of 100Extensively documentedVisit PeptidePlugs
Ascend Science$4.90/mg listed · 0 Ipamorelin certificates90.6of 100Extensively documentedVisit Ascend ScienceRanked on this compound's price per mg against the market median, with testing and documentation counted as they are overall. What a vial contains is answered by that vendor's certificates, not by the studies below.
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Early-phase human work on ipamorelinPubMed listingNull result | Human — controlled trial | Not recorded | — | A small early-phase human literature exists. The development programme was not carried forward to approval, and the listed work does not establish a durable clinical effect. | Listing |
| Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsInternational journal of colorectal disease · 2014 | Human — controlled trial | Not recorded | — | Postoperative ileus is a significant clinical challenge lacking effective management strategies. Ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract. This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074). The design was a multicenter, double-blind, placebo-con… | PMID 25331030 |
| Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersPharmaceutical research · 1999 | Human — controlled trial | Not recorded | — | To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers. A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level. Concentrations of ipamorelin and growth hormone were measured. The PK parameters showed dose-proportionality, with a short terminal … | PMID 10496658 |
The FDA maintains categorised lists of bulk drug substances nominated for use in compounding, including substances it has evaluated and placed in the category that may not be compounded. Several peptides tracked in this index have appeared in these evaluations. PepIndex records movements between categories here as they are observed; the linked page is the authoritative listing.
The World Anti-Doping Agency publishes an annual Prohibited List; class S2 covers peptide hormones, growth factors, related substances and mimetics. Several compounds tracked in this index fall within that class or its catch-all clause. The list is revised annually and takes effect on 1 January. PepIndex records revisions affecting indexed compounds here.
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Next Gen Peptides | 93.697% | 2 | Visit |
 Amino Club | 90.598% | 2 | Visit |
| Ascend Science | 88.994% | 0 | Visit |
| PeptidePlugs | 87.694% | 3 | Visit |
 Hydro Research Peptides | 83.989% | 1 | Visit |
 One Aminos | 82.789% | 1 | Visit |
 Modern Aminos | 81.197% | 2 | Visit |
 Bench Grade Peptides | 80.789% | 3 | Visit |
 Simple Peptide | 79.192% | 2 | Visit |
 NeuroLabs Research | 7991% | 1 | Visit |
 Ascension Peptides | 78.989% | 3 | Visit |
 Transition Biotech | 78.891% | 1 | Visit |
 Koi Peptides | 76.492% | 0 | Visit |
 Prime Peptides | 75.796% | 1 | Visit |
 Curo | 74.597% | 2 | Visit |
 Protide Health | 73.792% | 0 | Visit |
 Evo Labs Research | 73.387% | 0 | Visit |
| NLNorthline Labs | 7195% | 2 | Visit |
| GSGood Science Bio | 70.871% | 0 | Visit |
| EPEternal Peptides | 67.963% | 0 | Visit |
| GPGenX Peptides | 64.969% | 0 | Visit |
| EPEvolve Peptides | 6468% | 0 | Visit |
| TRTrue Research Labs | 6468% | 0 | Visit |
| LPLicensed Peptides | 61.487% | 1 | Visit |
| MHMile High Compounds | 60.591% | 0 | Visit |
| BPBiotech Peptides | 60.260% | 0 | Visit |
| VDVial Drop Labs | 59.474% | 1 | Visit |
| BLBioLongevity Labs | 5872% | 0 | Visit |
| EPExtreme Peptides | 57.980% | 1 | Visit |
| STSports Technology Labs | 50.771% | 0 | Visit |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.